Efficacy and safety of Telaprevir in patients with hepatitis C genotype 1 infection: The German Telaprevir early access program
H Wedemeyer, S Mauss, HW Busch, A Umgelter, P Buggisch, H Klinker, D Hüppe, A Hill, I Lonjon-Domanec, S Zeuzem · Zeitschrift für Gastroenterologie · 2014 · Heft 01
Bibliografische Angaben
Zusammenfassung
Background and aims: Anaemia is a common adverse event during treatment for HCV infection. HEP3002 is an ongoing, open-label, early access program of telaprevir in 16 countries, for patients with genotype 1 hepatitis C with severe fibrosis or compensated cirrhosis. This analysis is of the data from the 95 German patients, evaluated for 16 weeks of treatment. Methods: Liver biopsy or non-invasive tests showing severe fibrosis or cirrhosis were required at entry. 95 patients from Germany were treated with telaprevir in combination with peginterferon alfa and ribavirin (PR) for 12 weeks, followed by PR for 12 or 36…
